<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00584532</url>
  </required_header>
  <id_info>
    <org_study_id>200412146-5</org_study_id>
    <nct_id>NCT00584532</nct_id>
  </id_info>
  <brief_title>Effects of a Genistein Concentrated Polysaccharide (GCP) for Prostate Cancer on Active Surveillance.</brief_title>
  <acronym>GCP</acronym>
  <official_title>Effects of a Genistein Concentrated Polysaccharide (GCP) on Patients With a Diagnosis of Prostate Cancer on Active Surveillance.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Davis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, Davis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genistein Combined Polysaccharide (GCP) may play a role as a secondary chemopreventive agent
      in the treatment of localized prostate cancer.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2003</start_date>
  <completion_date type="Actual">December 2007</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in PSA levels in men on GCP</measure>
    <time_frame>6 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased PSA Doubling Time (PSADT)in men on GCP.</measure>
    <time_frame>6 Months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">66</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A=Placebo ARM of Study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>B=GCP Capsules. Ten 500 mg capsules per day for a total of 5 grams a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>10 Placebo Capsules taken orally every day.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Placebo capsules (contain cellulose only)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GCP - Genistein Combined Polysaccharide</intervention_name>
    <description>Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants must be male and have a pathological diagnosis of prostate cancer

          -  Pathological diagnosis of prostate cancer must be confirmed and on file with CRA prior
             to study entry.

          -  No treatment (surgery, radiation, or hormones) prior to study entry.

          -  PSA between 2.0 and 10.0 ng/ml.

          -  If PSA is &gt;10.0, patient must have been on Active Surveillance for 12 months prior to
             study initiation.

          -  No known allergy to soy or soy products.

          -  The patient is not currently taking more than 2 grams of genistein a day in
             nutritional or diet enhancing supplements (OTC supplements).

          -  Participant has not been on any previous GCP clinical trial.

          -  Normal Chemistry values prior to study entry.

        Exclusion Criteria:

          -  No pathological documentation of prostate cancer.

          -  Prior treatment for prostate cancer.

          -  PSA &gt;10.0 ng/ml but not on Active Surveillance for 12 months.

          -  Allergy to soy or soy products.

          -  Abnormal chemistry values.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Hackman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Davis - Dept. of Nutrition</affiliation>
  </overall_official>
  <verification_date>December 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 22, 2007</study_first_submitted>
  <study_first_submitted_qc>December 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 2, 2008</study_first_posted>
  <last_update_submitted>December 22, 2007</last_update_submitted>
  <last_update_submitted_qc>December 22, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2008</last_update_posted>
  <responsible_party>
    <name_title>Robert Hackman, PhD</name_title>
    <organization>University of California, Davis - Department of Nutrition</organization>
  </responsible_party>
  <keyword>Localized</keyword>
  <keyword>Prostate</keyword>
  <keyword>Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Genistein</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

